[1] Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer[J]. Nat Rev Dis Primers, 2017, 3(1): 17048. [2] Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells[J]. Cancer Res, 2006, 66(19): 9339-9344. [3] 蔡 昂, 向国辉, 杨全伟, 等. 张德忠运用旋覆代赭汤加减治疗上消化道肿瘤经验[J]. 中医肿瘤学杂志, 2020, 2(5): 63-66. [4] 刘亚婷, 刘 菊, 苗嘉萌, 等. 旋覆代赭汤对反流性食管炎大鼠模型TLR4/NF-κB的影响[J]. 中国中西医结合杂志, 2020, 40(1): 80-84. [5] 黄 棪, 徐明英, 夏雪皎, 等. 旋覆代赭汤对胆碱能抗炎通路相关RE大鼠炎症因子的影响[J]. 天津中医药大学学报, 2018, 37(5): 386-389. [6] 唐丽明, 宋 宁, 张桂贤, 等. 加味旋覆代赭汤对非酸反流所致慢性食管病变大鼠肠化及CDX2、DLK1表达的影响[J]. 中国中西医结合外科杂志, 2020, 26(1): 2-7. [7] 陈丽娟, 王向群, 余杨桦, 等. 旋覆代赭汤治疗功能性消化不良及对胃肠激素影响的临床观察[J]. 中华中医药学刊, 2019, 37(2): 417-420. [8] 杨梦婷, 高 乐, 王 相, 等. 经典名方旋覆代赭汤的研究进展[J]. 中药药理与临床, 2021, 37(3): 214-221. [9] Pophali P, Halland M. Barrett's oesophagus: diagnosis and management [J]. BMJ, 2016, 353: i2373. [10] Vaira D, Gatta L, Ricci C, et al. Gastroesophageal reflux disease and Barrett's esophagus[J]. Intern Emerg Med, 2011, 6(4): 299-306. [11] 任吉莲, 崔灵芝, 郝小夏, 等. 厚朴酚联合吉非替尼对A549非小细胞肺癌细胞的干预作用[J]. 中国应用生理学杂志, 2021, 37(5): 506-510. [12] 曹启迪, 逯艳艳, 马颖才. 食管癌的早诊早治 [J]. 临床消化病杂志, 2021, 33(2): 141-143. [13] Short M, Burgers K, Fry V. Esophageal cancer [J]. Am Fam Physician, 2017, 95(1): 22-28. [14] 文 珍, 张彦秋, 吴 蓉, 等. 首发为食管鳞癌的多原发癌患者临床特征及生存分析 [J]. 中国应用生理学杂志, 2021, 37(4): 407-414. [15] 马长德, 张超云. 旋覆代赭汤加味治疗中晚期食管癌19例[J]. 中医临床研究, 2011, 3(19): 53-54. [16] 黄兆迁. 旋覆代赭汤加减治疗食管癌38例的体会 [J]. 医学信息(中旬刊), 2011, 24(1): 334. [17] Lu P, Liang QD, Li R, et al. Effect of traditional Chinese medicine on survival and quality of life in patients with esophageal carcinoma after esophagectomy[J]. Chin J Integr Med, 2006, 03): 175-179. [18] 刘浩江. 旋覆代赭汤治疗食管癌手术后並发症46例[J]. 河南中医, 1987, 7(1): 22. [19] 崔 亚, 姜礼双, 卜 平. 旋覆代赭汤实验研究及临床应用进展 [J]. 江苏中医药, 2018, 50(1): 82-85. [20] 袁红霞, 田晶晶, 闫早兴. 中医药治疗反流性食管炎研究近况 [J]. 世界华人消化杂志, 2016, 24(32): 4323-4329. [21] Wang K, Zhang L, He ZH, et al. A population-based survey of gastroesophageal reflux disease in a region with high prevalence of esophageal cancer in China[J]. Chin Med J (Engl), 2019, 132(13): 1516-1523. [22] Uko N, Güner O, Matesic D, et al. Akt pathway inhibitors[J]. Curr Top Med Chem, 2020, 20(10): 883-900. [23] 阿 友, 孟祥宁, 刘改云, 等. EGF通过激活FAK-P13K/AKT途径促进肺癌细胞增殖[J]. 国际遗传学杂志, 2007(4): 241-243. [24] Gao H, Wang H, Peng J. Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells[J]. Cell Biochem Biophys, 2014, 69(1): 27-34. [25] Ma X, Bai Y. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin[J]. Mol Med Rep, 2012, 6(6): 1433-1437. [26] Wang Z, Kang L, Zhang H, et al. AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation[J]. Oncogene, 2019, 38(26): 5250-5264. |